Leonard Achiron
Vision Therapy · Hapeville, GANPI 1578667986
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 56.3% of the total. Reporting peaked in 2019 at $949 and has fallen 78.8% since, to $201 in 2025.
Across 31 payments — averaging $51.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$905
- Mallinckrodt Hospital Products Inc.$182
- Alcon$128
- Novartis$87
- Glaukos Corporation$78
- Bausch & Lomb Americas Inc.$58
- plus $168 from 5 others
What the payments were for
- Travel & lodging$61138%
- Food & beverage$88955%
- Education$885%
- Entertainment$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 2 | $905 |
| Mallinckrodt Hospital Products Inc. | 5 | $182 |
| Alcon | 3 | $128 |
| Novartis | 5 | $87 |
| Glaukos Corporation | 2 | $78 |
| Bausch & Lomb Americas Inc. | 4 | $58 |
| AbbVie(2 entities) | 2 | $45 |
| Coopervision Inc. | 3 | $41 |
| Biotissue Holdings Inc. | 2 | $32 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $30 |
| Optos, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few vision therapy providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Restasis MultidoseCyclosporine | 36 | $24,331 |
| RestasisCyclosporine | 21 | $17,982 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $7,903 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $5,521 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $3,046 |
| Loteprednol Etabonate | 14 | $2,564 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $961 |
| Timolol Maleate | 27 | $846 |
| Latanoprost | 42 | $800 |
| Prednisolone Acetate | 18 | $728 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis Multidose, Restasis, Combigan | $45 | $47,83475 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $30 | $2,56414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vision therapy providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other vision therapy in Hapeville
- Jennifer DattoloWoodstock$37K
- Sharon Berger-MoscowRoswell$7K
- James WoodLilburn$4K
- Rachel SweeneyAtlanta$3K
- Nadira ShadeedDacula$1K
- James BehrensAtlanta$874
- David CookMarietta$838
- Alayna LarsenRoswell$482
- Janna IyerRoswell$195
- Kimberly LinertCumming$121
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.